These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 7693418)

  • 1. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of epirubicin.
    Robert J
    Clin Pharmacokinet; 1994 Jun; 26(6):428-38. PubMed ID: 8070217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
    Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
    J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer.
    Jakobsen P; Steiness E; Bastholt L; Dalmark M; Lorenzen A; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS
    Cancer Chemother Pharmacol; 1991; 28(1):63-8. PubMed ID: 2040035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
    Danesi R; Innocenti F; Fogli S; Gennari A; Baldini E; Di Paolo A; Salvadori B; Bocci G; Conte PF; Del Tacca M
    Br J Clin Pharmacol; 2002 May; 53(5):508-18. PubMed ID: 11994057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
    Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
    Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
    Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
    Robert J; Monnier A; Poutignat N; Hérait P
    Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
    Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
    J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.
    Camaggi CM; Comparsi R; Strocchi E; Testoni F; Angelelli B; Pannuti F
    Cancer Chemother Pharmacol; 1988; 21(3):221-8. PubMed ID: 3162849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.
    Ganzina F
    Cancer Treat Rev; 1983 Mar; 10(1):1-22. PubMed ID: 6342772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
    Plosker GL; Faulds D
    Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
    Kaklamani VG; Gradishar WJ
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S26-33. PubMed ID: 12756076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.
    Coukell AJ; Faulds D
    Drugs; 1997 Mar; 53(3):453-82. PubMed ID: 9074845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Hortobagyi GN; Yap HY; Kau SW; Fraschini G; Ewer MS; Chawla SP; Benjamin RS
    Am J Clin Oncol; 1989 Feb; 12(1):57-62. PubMed ID: 2643296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
    Basser RL; Sobol MM; Duggan G; Cebon J; Rosenthal MA; Mihaly G; Green MD
    J Clin Oncol; 1994 Aug; 12(8):1659-66. PubMed ID: 8040678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.